Glucagon-Like Peptide-1 Analog and Insulin Combination Therapy in the Management of Adults with Type 2 Diabetes Mellitus

Abstract

Spanish

French

Objective:

To evaluate the efficacy and tolerability of combination glucagon-like peptide-1 (GLP-1) analogs and insulin in the management of type 2 diabetes mellitus (T2DM) in adults.

Data Source:

A MEDLINE search (1966–April 2010) was conducted using the key terms glucagon-like peptide-1 analog, exenatide, incretin mimetic, liraglutide, diabetes mellitus, and insulin.

Study Selection and Data Extraction:

All English-language articles identified from the data source were evaluated and reviewed for inclusion. Original research and retrospective cohorts were included in this review. The references of articles that we identified were examined for any additional studies appropriate for review.

Data Synthesis:

Exenatide is a subcutaneously administered GLP-1 receptor agonist that is used for the improvement of glycemic control in adults with T2DM. Through actions similar to those of endogenous GLP-1, exenatide contributes to improved postprandial glycemic control and weight loss. The concomitant use of exenatide and insulin is currently not Food and Drug Administration-approved due to lack of clinical trial data. However, combination insulin and exenatide may be advantageous, especially for reducing weight gain, particularly for obese patients with T2DM. Several small prospective and retrospective studies evaluating combination therapy found statistically significant reductions in hemoglobin A_1c (A1C), weight, and total daily insulin dose requirements. The most common adverse effects reported included gastrointestinal effects, such as nausea and vomiting, and hypoglycemia.

Conclusions:

Although there is a limited amount of data and not all studies demonstrated A1C reduction, the combination of exenatide with insulin therapy appears to be a safe option in the management of T2DM. It may be a promising therapeutic strategy for some patients, as reductions in weight and insulin doses were observed. Further well-designed prospective trials are warranted to fully determine the long-term effectiveness and safety of this combination as well as its place in therapy.

Keywords

exenatide insulin liraglutide type 2 diabetes mellitus

Get full access to this article

View all access options for this article.

References

American Diabetes Association. National diabetes fact sheet, 2007. www.diabetes.org/diabetes-basics/diabetes-statistics/ (accessed 2010 Jan 23).

Standards of medical care in diabetes—2010. Diabetes Care 2010;33(suppl 1):S11-61.

Centers for Disease Control and Prevention, National Center for Health Statistics. www.cdc.gov/diabetes/statistics/meduse/fig1.htm (accessed 2010 Jan 23).

Product information. Byetta (exenatide). San Diego, CA: Amylin Pharmaceuticals, Inc., October 2009.

Robles

, Singh-Franco

A review of exenatide as adjunctive therapy in patients with type 2 diabetes. Drug Des Devel Ther 2009;3:219-40.

Govindan

, Healey

, Kalupahana

. Exenatide therapy in insulin treated patients with type 2 diabetes and obesity (abstract 884). Diabetologia 2008;51(suppl 1):S352-3.

Samarasinghe

, Shlomowitz

, Munro

. The short term effects of exenatide therapy in insulin treated patients with type 2 diabetes mellitus—a new option to achieve weight loss (abstract 885). Diabetologia 2008;51(suppl 1):S353.

Christofidis

, Boyle

, Johnson

. Real world clinical experience with exenatide, a long term study on weight and A1C control (abstract 572-P). Diabetes 2009;58(suppl 1):A154.

Bhatia

, Viswanathan

, Chaudhuri

. Exenatide causes weight loss and a reduction in the insulin dose along with an improvement in HbA1C in obese type 2 diabetics on insulin (abstract 442-P). Diabetes 2006;55(suppl 1):A105.

10.

Oyer

, Crawford

, Shah

. Exenatide in diabetic patients on insulin and TZDs (abstract 2038-PO). Diabetes 2006;55(suppl 1):A471-2.

11.

Viswanathan

, Chaudhuri

, Bhatia

. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 2007;13:444-50.

12.

Hood

. Exenatide (EXE) use in T2DM with A1C ≤7% (abstract 488-P). Diabetes 2006;55(suppl 1):A116.

13.

Sheffield

, Kane

, Busch

. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract 2008;14:285-92.

14.

Yoon

, Cavaghan

, Brunelle

. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther 2009;31:1511-23.

15.

John

, Kane

, Busch

. Expanded use of exenatide in the management of type 2 diabetes. Diabetes Spectrum 2007;20:59-63.

16.

Linnebjerg

, Kothare

, Park

. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007;64:317-27.

17.

Johansen

, Whitfield

Exenatide may aggravate moderate diabetic renal impairment: a case report. Br J Clin Pharmacol 2008;66:568-9.

18.

Adjunctive therapy of exenatide or sitagliptin to insulin glargine in type 2 diabetes (identifier: NCT00971659). www.clinicaltrials.gov (accessed 2010 Jan 23).

19.

Comparison of two basal insulins for patients with type 2 diabetes taking oral diabetes medicines and exenatide. (Identifier: NCT00560417). www.clinicaltrials.gov (accessed 2010 Jan 23).

20.

Addition of exenatide to insulin glargine in type 2 diabetes mellitus. (Identifier: NCT00765817). www.clinicaltrials.gov (accessed 2010 Jan 23).

21.

A new treatment strategy of adding exenatide to insulin therapy for patients with type 2 diabetes (T2DM) and non-alcoholic fatty liver disease (NAFLD). (Identifier: NCT01006889). www.clinicaltrials.gov (accessed 2010 Jan 23).

22.

How glargine insulin, oral diabetes medications and exenatide may improve blood sugar control and weight gain in type 2 diabetics (MEXELIN). (Identifier. NCT00667732). www.clinicaltrials.gov (accessed 2010 Jan 23).

23.

A trial comparing two therapies: basal insulin/glargine, exenatide and metformin (BET) or basal insulin/glargine, bolus insulin lispro and metformin (BBT) in subjects with type 2 diabetes. (Identifier: NCT00960661). www.clinicaltrials.gov (accessed 2010 Jan 23).

24.

The effect of insulin detemir in combination with liraglutide and metformin compared with liraglutide and metformin in subjects with type 2 diabetes. (Identifier: NCT00856986). www.clinicaltrials.gov (accessed 2010 Mar 11).

25.

Examination of the effects of liraglutide on the mode of action of insulin detemir. (Identifier: NCT00873223). www.clinicaltrials.gov (accessed 2010 Mar 11).